FindTrial
Sign In

Does platelet rich plasma help in early osteoarthritis knee? If so does more than one dose help more?

EFFECTIVENESS OF SINGLE DOSE VERSUS MULTIDOSE INTRA ARTICULAR INJECTION OF PLATELET RICH PLASMA IN EARLY OSTEOARTHRITIS OF KNEE - A RANDOMISED CONTROL SINGLE BLIND TRIAL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/04/008406
Enrollment
90
Registered
2017-04-24
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Early osteoarthritis of knee

Interventions

Intervention1: Single dose of intraarticular platelet rich plasma: Single dose of intraarticular platelet rich plasma along with physiotherapy and exercises as modality of treatment of early osteoarth

Sponsors

Sri Sathya Sai Institute of Higher Medical Sciences Prasanthigram
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Grade 1, Grade 2 OA knee as per Kellgren - Lawrence radiographic staging. 2) Patients who give consent for treatment with platelet rich plasma as per our protocol. 3) Patients with stable knees, normal tibiofemoral alignment,or patellofemoral tracking.

Exclusion criteria

Exclusion criteria: 1) Osteoarthritis secondary to joint inflammatory diseases (eg- rheumatoid arthritis, ankylosing spondylitis etc). 2)Patients with other diseases, affecting the knee joint like crystal arthropathy, symptomatic chondrocalcinosis, acute synovitis, excessive joint effusion( >100ml), cystic disease around the knee joint(eg-popliteal cyst). 3) Patients with generalized osteoarthritis. 4) Metabolic disease of the bone. 5) Patients with co-existing low back ache. 6) Late stages of osteoarthritis. 7) Intra articular injections within the previous three months. 8) Pertaining to platelet concentrate use - h/o thrombocytopenia, use of anticoagulant therapy, active infection, malignancies. 9) Patients with abnormal leucocyte count. 10) Patients with blood diseases, systemic metabolic, immunodeficiency state. 11) Local or generalised infection. 12)Varus-valgus malalignment above 5°, patellofemoral maltracking or untreated instability. 13)History of prior arthroscopic or surgical intervention of knee. 14) Treatment with corticosteroids

Design outcomes

Primary

MeasureTime frame
Pain assessment by Visual Analog SoreTimepoint: pretreatment and 3, 6 and 12 months—

Secondary

MeasureTime frame
Quality of life by International Knee Documentation Committee(IKDC), Knee Injury and Osteoarthritis Outcome Score (KOOS), Tegner Activity Level Scale Timepoint: pre treatment, 3, 6 and 12 months after treatment—

Countries

India

Contacts

Public ContactRajkumar Reddy Alguvelly

Sri Sathya Sai Institute of Higher Medical Sciences - Prasanthigram

drkoushik@hotmail.com9491629620

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026